Monday, March 29, 2021 3:14:11 PM
New York Yankees and Duke Basketball
Recent EWTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 01:10:10 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/10/2024 01:07:23 PM
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 • Business Wire • 05/10/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/09/2024 01:21:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 12:06:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:51 PM
- Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • Business Wire • 05/09/2024 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/07/2024 01:16:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 01:14:06 PM
- Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors • Business Wire • 05/07/2024 12:00:00 PM
- Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) • Business Wire • 05/06/2024 12:00:00 PM
- Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies • Business Wire • 04/23/2024 12:00:00 PM
- Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) • Business Wire • 04/15/2024 08:05:00 PM
- Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session • Business Wire • 03/28/2024 12:00:00 PM
- Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 • Business Wire • 03/27/2024 12:00:00 PM
- Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 • Business Wire • 03/05/2024 01:00:00 PM
- Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference • Business Wire • 02/28/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 01:07:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:00:13 PM
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • Business Wire • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:43:00 PM
- Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) • Business Wire • 02/13/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:42:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/07/2024 09:15:46 PM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM